Prospect of anticancer therapy.
作者信息
Park Hee-Sook
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea.
出版信息
Cancer Res Treat. 2004 Apr;36(2):100-2. doi: 10.4143/crt.2004.36.2.100. Epub 2004 Apr 30.
Abstract
摘要
相似文献
1
Prospect of anticancer therapy.
Cancer Res Treat. 2004 Apr;36(2):100-2. doi: 10.4143/crt.2004.36.2.100. Epub 2004 Apr 30.
2
Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies.
Curr Top Med Chem. 2021;21(5):404-425. doi: 10.2174/1568026620666200616143247.
3
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.
Oncotarget. 2017 Jul 11;8(28):46635-46651. doi: 10.18632/oncotarget.16743.
4
PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium.
Clin Colorectal Cancer. 2016 Sep;15(3):243-9. doi: 10.1016/j.clcc.2016.02.003. Epub 2016 Feb 13.
5
Exploring the Leaves of L. as a Source of Potential Anti-inflammatory and Anticancer Agents.
Front Pharmacol. 2018 Jun 20;9:661. doi: 10.3389/fphar.2018.00661. eCollection 2018.
6
An extended PROSPECT: Advance in the leaf optical properties model separating total chlorophylls into chlorophyll a and b.
Sci Rep. 2017 Jul 25;7(1):6429. doi: 10.1038/s41598-017-06694-y.
7
Protein threading using PROSPECT: design and evaluation.
Proteins. 2000 Aug 15;40(3):343-54.
8
Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21.
9
Functional analysis of concealment: a novel application of prospect and refuge theory.
Behav Processes. 2012 Sep;91(1):22-5. doi: 10.1016/j.beproc.2012.05.003. Epub 2012 May 27.
10
Comparison of the ProSpecT and Color Vue enzyme-linked immunoassays for the detection of Cryptosporidium in stool specimens.
Diagn Microbiol Infect Dis. 1994 Aug;19(4):221-5. doi: 10.1016/0732-8893(94)90035-3.
本文引用的文献
1
Practical management of patients with chronic myeloid leukemia receiving imatinib.
J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13.
2
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038.
3
Imatinib mesylate--a new oral targeted therapy.
N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339.
4
Development of matrix metalloproteinase inhibitors in cancer therapy.
J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. doi: 10.1093/jnci/93.3.178.
5
New therapeutic agents targeting the epidermal growth factor receptor.
J Clin Oncol. 2000 Nov 1;18(21 Suppl):54S-9S.
6
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
Radiat Res. 2000 Aug;154(2):125-32. doi: 10.1667/0033-7587(2000)154[0125:fiptae]2.0.co;2.
7
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
J Clin Invest. 2000 Jan;105(1):3-7. doi: 10.1172/JCI9083.
8
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Cancer Res. 1999 Jul 15;59(14):3374-8.
9
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7.
10
Gene therapy strategies for tumor antiangiogenesis.
J Natl Cancer Inst. 1998 Feb 18;90(4):273-86. doi: 10.1093/jnci/90.4.273.
Zotero 插件